Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 1
2007 2
2008 4
2009 4
2010 5
2011 3
2012 7
2013 23
2014 17
2015 9
2016 21
2017 15
2018 5
2019 9
2020 3
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 25703891

115 results

Results by year

Filters applied: . Clear all
Page 1
The arranged marriage of cangrelor and bivalirudin.
Montalescot G, Helft G. Montalescot G, et al. JACC Cardiovasc Interv. 2015 Mar;8(3):434-435. doi: 10.1016/j.jcin.2015.01.004. Epub 2015 Feb 18. JACC Cardiovasc Interv. 2015. PMID: 25703891 Free article. No abstract available.
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
White HD, Bhatt DL, Gibson CM, Hamm CW, Mahaffey KW, Price MJ, Steg PG, Stone GW, Cortese B, Wilensky M, Deliargyris EN, Liu T, Prats J, Harrington RA. White HD, et al. JACC Cardiovasc Interv. 2015 Mar;8(3):424-433. doi: 10.1016/j.jcin.2014.09.025. Epub 2015 Feb 18. JACC Cardiovasc Interv. 2015. PMID: 25703887 Free article. Clinical Trial.
Platelet inhibition with cangrelor.
Lippi G, Franchini M, Favaloro EJ. Lippi G, et al. N Engl J Med. 2010 Mar 18;362(11):1049; author reply 1049. N Engl J Med. 2010. PMID: 20301798 No abstract available.
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Abtan J, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm CW, Price MJ, Abnousi F, Prats J, Deliargyris EN, White HD, Harrington RA, Bhatt DL; CHAMPION PHOENIX Investigators. Abtan J, et al. JACC Cardiovasc Interv. 2016 Sep 26;9(18):1905-13. doi: 10.1016/j.jcin.2016.06.046. JACC Cardiovasc Interv. 2016. PMID: 27659566 Free article. Clinical Trial.
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial.
Vaduganathan M, Harrington RA, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL. Vaduganathan M, et al. Circ Cardiovasc Interv. 2016 Jun;9(6):e003612. doi: 10.1161/CIRCINTERVENTIONS.116.003612. Circ Cardiovasc Interv. 2016. PMID: 27313282 Free PMC article. Clinical Trial.
115 results